Is Wave Life Sciences Ltd. (WVE) a Buy, Sell, or Hold?
NASDAQ : WVE
Wave Life Sciences Ltd.
$5.89 USD
-$0.03 (-0.51%)
- Volume
- 2.75M
- Average Volume
- 3.42M
- Market Capitalization
- $1.13B
- P/E Ratio
- -5.56
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $21.73
- Year Low
- $5.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.26
Company Overview
NASDAQ
Paul Bolno
Biotechnology
Healthcare
WVE
317
SG
USD
Liquidity Metrics
0.03
11.26
11.26
10.93
0.00
Sales & Valuation
$42.73M
15.78
2.30
-6.18
-0.92
Profitability
-$1.21
-$204.38M
-255.70%
-255.70%
-56.41%
-31.46%
P/E Metrics
-5.56
0.10
0.10
Analyst Price Target & Rating
$15.00
$43.00
$13.00
2/5
25 Analysts
-60.73%
Financial Health Scores
6.23
3/9
$511.44M
$583.54M
$71.81M
-$183.59M
Key Metrics (TTM)
$610.15M
8.50
-3.49
11.26
-56.41%
-36.32%
-15.49%
-16.10%
-1561 days
Company Executives
| Name | Title |
|---|---|
| Kyle Moran | Chief Financial Officer & Principal Accounting Officer |
| Sridhar Vaddeboina | Senior Vice President of Chemistry, Manufacturing & Controls |
| Daryn Lewis | Senior Vice President & Head of Human Resources |
| Chandra Vargeese | Chief Technology Officer |
| Erik Ingelsson | Chief Scientific Officer |
| Gregory L. Verdine | Founder & Director |
| Paul Bolno | President, Chief Executive Officer & Director |
| Kate Rausch | Head of Investor Relations |
| Christopher Francis | Senior Vice President of Corporate Development & Head of Emerging Areas |
| Linda Rockett | Senior Vice President & General Counsel |
Poll Results
No votes yet today — be the first to share your view!
About Wave Life Sciences Ltd. (NASDAQ:WVE) Stock
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne ... muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
2026-07-23 08:30:00
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company's second quarter 2026 financial results and provide business updates.
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
2026-07-22 13:02:12
Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for July 22nd
2026-07-22 08:17:14
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
2026-07-20 11:51:04
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
2026-07-07 16:15:00
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the “Singapore Court”).
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
2026-07-01 10:55:14
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2026-06-24 08:30:00
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
2026-06-16 13:02:24
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Frequently Asked Questions
-
What is the current Wave Life Sciences Ltd. (WVE) stock price?
-
Wave Life Sciences Ltd.(NASDAQ:WVE) stock price is $5.89 in the last trading session. During the trading session, WVE stock reached the peak price of $21.73 while $5.02 was the lowest point it dropped to. The percentage change in WVE stock occurred in the recent session was --0.51% while the dollar amount for the price change in WVE stock was -$0.03.
-
WVE's industry and sector of operation?
-
The NASDAQ listed WVE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of WVE?
-
Kyle Moran | Chief Financial Officer & Principal Accounting Officer
Sridhar Vaddeboina | Senior Vice President of Chemistry, Manufacturing & Controls
Daryn Lewis | Senior Vice President & Head of Human Resources
Chandra Vargeese | Chief Technology Officer
Erik Ingelsson | Chief Scientific Officer -
How many employees does WVE have?
-
Number of WVE employees currently stands at 317. WVE operates from Marina One East Tower, Singapore, CE 018936, SG.
-
Link for WVE official website?
-
Official Website of WVE is: https://wavelifesciences.com
-
How do I contact WVE?
-
WVE could be contacted at phone #65 6236 3388 and can also be accessed through its website. WVE operates from Marina One East Tower, Singapore, CE 018936, SG.
-
How many shares of WVE are traded daily?
-
The average number of WVE shares traded daily for last 3 months was 3.42M.
-
What is the market cap of WVE currently?
-
The market value of WVE currently stands at $1.13B with its latest stock price at $5.89